Table 1.
Characteristics of patients with Behçet's disease (BD) whose peripheral blood mononuclear cells were analysed in this study.
| Patients | Gender | Age (years) | Disease duration (years) | Disease type | Medication | |
|---|---|---|---|---|---|---|
| BD5 | M | 48 | 16 | C | (E, M) | PSL 3 mg/day |
| BD6 | F | 38 | 5 | I | (M, C, A) | PSL 5 mg/day |
| BD7 | M | 37 | 15 | C | (E, M, C, A) | COL 0·5 mg/day |
| BD8 | F | 45 | 4 | C | (E, M C, A) | COL 0·5 mg/day |
| BD9 | M | 30 | 1 | I | (M, C, A) | COL 1 mg/day |
| BD10 | F | 36 | 5 | I | (M, C, A) | COL 0·5 mg/day |
| BD11 | F | 28 | 8 | C | (E, M C, A) | COL 0·5 mg/day, PSL 5 mg/day |
| BD12 | M | 28 | 2 | I | (M, C, A) | PSL 5 mg/day |
C, complete type; I, incomplete type; E, eye symptom; M, mucosal symptom; C, cutaneous symptom; A, arthralgia; COL, colchicine; PSL, prednisone.